- Home
- NDLS vs LGVN Comparison
NDLS vs LGVN Comparison
Compare NDLS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- LGVN
- Stock Information
- Founded
- NDLS 1995
- LGVN 2014
- Country
- NDLS United States
- LGVN United States
- Employees
- NDLS N/A
- LGVN N/A
- Industry
- NDLS Restaurants
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- NDLS Consumer Discretionary
- LGVN Health Care
- Exchange
- NDLS Nasdaq
- LGVN Nasdaq
- Market Cap
- NDLS 32.9M
- LGVN 28.4M
- IPO Year
- NDLS 2013
- LGVN 2021
- Fundamental
- Price
- NDLS $0.69
- LGVN $1.74
- Analyst Decision
- NDLS Strong Buy
- LGVN Strong Buy
- Analyst Count
- NDLS 2
- LGVN 3
- Target Price
- NDLS $3.00
- LGVN $8.67
- AVG Volume (30 Days)
- NDLS 184.6K
- LGVN 325.0K
- Earning Date
- NDLS 11-06-2024
- LGVN 11-12-2024
- Dividend Yield
- NDLS N/A
- LGVN N/A
- EPS Growth
- NDLS N/A
- LGVN N/A
- EPS
- NDLS N/A
- LGVN N/A
- Revenue
- NDLS $495,817,000.00
- LGVN $1,852,000.00
- Revenue This Year
- NDLS N/A
- LGVN $161.78
- Revenue Next Year
- NDLS $0.14
- LGVN $40.89
- P/E Ratio
- NDLS N/A
- LGVN N/A
- Revenue Growth
- NDLS N/A
- LGVN 141.46
- 52 Week Low
- NDLS $0.60
- LGVN $0.77
- 52 Week High
- NDLS $3.50
- LGVN $21.30
- Technical
- Relative Strength Index (RSI)
- NDLS 42.72
- LGVN 34.75
- Support Level
- NDLS $0.67
- LGVN $1.80
- Resistance Level
- NDLS $0.74
- LGVN $2.15
- Average True Range (ATR)
- NDLS 0.06
- LGVN 0.12
- MACD
- NDLS 0.02
- LGVN -0.02
- Stochastic Oscillator
- NDLS 60.00
- LGVN 4.42
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.